Abstract
In the present study, a highly sensitive and reproducible bio-analytical method was developed using LC–ESI-MS/MS to assess the lower plasma levels of bortezomib in multiple myeloma patients. The gradient elution was optimized using reverse-phase C18 column with mobile phases consisting of water and acetonitrile in 0.1% formic acid. Multiple reaction monitoring mode was used for quantification using precursor-to-product ion transition for bortezomib and sulfadiamethoxine was used as internal standard. This method was validated with a linearity range of 0.195–25 ng mL−1. Intra-day and inter-day accuracy was 99.17–101.89% and 95.01–102.92% with precision of < 9.87% and < 8.77%, respectively. Bortezomib was stable in plasma samples stored at − 80 °C for up to 10 months. The lower limit of quantification was found to be 0.195 ng mL−1. This method was also found to be capable of quantifying bortezomib trough levels (ranging 0.19–0.7 ng mL−1) in plasma of multiple myeloma patients post-cycle 1–6. Bortezomib content in the commonly prescribed generic formulations was also studied. The concentration in all formulations was within the 90–110% of the innovator, as prescribed by the USFDA, ruling out their role blood level variation. The study supports the use of this method for trough level estimation and therapeutic drug monitoring of bortezomib in multiple myeloma patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Code Availability
Not applicable.
References
Rosinol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernandez MT, Martinez-Martinez R, Moraleda JM, Jarque I, Bargay J, Gironella M, Arriba FD, Palomera L, Gonzalez-Montes Y, Marti JM, Krsnik I, Arguinano JM, Gonzalez ME, Gonzalez AP, Casado LF, Lopez-Anglada L, Paiva B, Mateos MV, Miguel JFS, Lahuerta JJ, Blade J (2019) Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. https://doi.org/10.1182/blood.2019000241
Attal M, Lauwers-cances V, Hulin C, Pessac B, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P (2017) Lenalidomide, bortezomib, and dexamethasone with transplantation in myeloma. N Engl J Med. https://doi.org/10.1056/NEJMoa1611750
Liu ZA, Xia HL, Li CJ, Xia L (2019) Incidence and risk of peripheral neuropathy caused by intravenous and subcutaneous injection of bortezomib. Zhongguo Shi Yan Xue Ye Xue Za Zhi. https://doi.org/10.19746/j.cnki.issn.1009-2137.2019.05.046 (Chinese)
Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. https://doi.org/10.1200/JCO.2004.02.106
Andriamanana I, Gana I, Duretz B, Hulin A (2013) Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B. https://doi.org/10.1016/j.jchromb.2013.01.037
Shu C, Zeng T, Gao S, Xia T, Huang L, Zhang F, Chen W (2016) LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients. J Chromatogr B. https://doi.org/10.1016/j.jchromb.2016.06.009
Zhang L, Mager DE (2015) Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice. J Pharmacokinet Pharmacodyn. https://doi.org/10.1007/s10928-015-9445-x
Ruschak AM, Slassi M, Kay LE, Schimmer AD (2011) Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djr160
Jones MR, Urits I, Wolf J, Corrigan D, Colburn L, Peterson E, Williamson A, Viswanath O (2020) Drug-induced peripheral neuropathy: a narrative review. Curr Clin Pharmacol. https://doi.org/10.2174/1574884714666190121154813
Arora B, Narayanasamy A, Nirmal J, Halder N, Patnaik S, Ravi AK, Velpandian T (2014) Development and validation of a LC-MS/MS method for homocysteine thiolactone in plasma and evaluation of its stability in plasma samples. J Chromatogr B. https://doi.org/10.1016/j.jchromb.2013.11.011
Imre S, Vlase L, Muntean DL (2008) Bioanalytical method validation. Rev Rom Med Lab 10:13–21
Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G (2005) Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. https://doi.org/10.1124/dmd.104.002956
Deshantri AK, Metselaar JM, Zagkou S, Storm G, Mandhane SN, Fens MHAM, Schiffelers RM (2019) Development and characterization of liposomal formulation of bortezomib. Int J Pharm. https://doi.org/10.1016/j.ijpx.2019.100011
Moreau P, Coiteux V, Hulin C, Leleu X, Van De Velde H, Acharya M, Harousseau JL (2008) Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica. https://doi.org/10.3324/haematol.13285
Byrn SR, Tishmack PA, Milton MJ, van de Velde H (2011) Analysis of two commercially available bortezomib products: differences in assay of active agent and impurity profile. AAPS Pharm Sci Tech. https://doi.org/10.1208/s12249-010-9554-1
Acknowledgements
We are grateful to Glenmark Pharmaceuticals for the bortezomib active pharmaceutical ingredient as a gift sample. We acknowledge DST-FIST for providing High Precision Bio-analytical Facility (HPBAF) at Ocular Pharmacology and Pharmacy Division, Dr. RPC, AIIMS, New Delhi (India).
Funding
We thank the Department of Science and Technology for funding the project (Code: EMR/2016/003309).
Author information
Authors and Affiliations
Contributions
LG and USD: conduct of experiments, data collection and analysis, preparation of draft manuscript; PG: study concept and design, data curation, revision of the manuscript and final approval; TV: data interpretation, revision of the manuscript and final approval; LK: data analysis, revision of the manuscript and final approval; YKG: study concept, revision of the manuscript and final approval; AS and KL: data review, revision of manuscript and final approval.
Corresponding author
Ethics declarations
Conflict of Interest
The authors have no relevant financial or non-financial interests to disclose. There were no potential conflicts of interest.
Ethical Approval
The study was approved by the Institute Ethics Committee.
Consent to Participate
All participants provided written informed consent.
Consent for Publication
Not applicable.
Research Involving Human and Animal Participants
The study was conducted in human participants after ethics approval (reference no: IECPG-482/29.08.2016).
Informed Consent
The participants were explained about the study and informed consent was signed by them before enrollment.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Goel, L., Das, U.S., Gupta, P. et al. Development and Validation of Highly Sensitive LC–ESI-MS/MS Method for Bortezomib and Its Applications for Plasma Levels and Drug Content of Branded and Generic Formulations in India. Chromatographia 85, 127–135 (2022). https://doi.org/10.1007/s10337-021-04121-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10337-021-04121-z